Is JetBlue The Best Airline Stock?
Following a general trend of improvement among airline stocks, shares…
Sell
28
INCR Quote, Financials, Valuation and Earnings
Last price:
$1.24
Seasonality move
:
4.38%
Day range:
$1.23 - $1.25
52-week range:
$1.22 - $1.79
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.49x
P/B ratio:
0.51x
Volume:
6K
Avg. volume:
16.1K
1-year change:
-11.81%
Market cap:
$69.4M
Revenue:
$64.5M
EPS (TTM):
-$0.11
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
INCR
InterCure Ltd.
|
-- | -- | -- | -- | -- |
|
CANF
Can-Fite BioPharma Ltd.
|
-- | -- | -3.23% | -72.97% | $3.50 |
|
CGEN
Compugen Ltd.
|
$1.5M | -$0.09 | 10.1% | -9.81% | $6.25 |
|
NSRX
Nasus Pharma
|
-- | -- | -- | -- | -- |
|
PHGE
BiomX, Inc.
|
-- | -$6.08 | -- | -206.85% | $399.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
INCR
InterCure Ltd.
|
$1.27 | -- | $69.4M | -- | $0.00 | 0% | 0.49x |
|
CANF
Can-Fite BioPharma Ltd.
|
$0.32 | $3.50 | $5M | -- | $0.00 | 0% | 1.77x |
|
CGEN
Compugen Ltd.
|
$1.65 | $6.25 | $154.3M | 55.83x | $0.00 | 0% | 22.05x |
|
NSRX
Nasus Pharma
|
-- | -- | -- | -- | $0.00 | 0% | -- |
|
PHGE
BiomX, Inc.
|
$2.44 | $399.00 | $3.7M | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
INCR
InterCure Ltd.
|
22.42% | -0.270 | 38.4% | 1.15x |
|
CANF
Can-Fite BioPharma Ltd.
|
-- | 0.899 | -- | -- |
|
CGEN
Compugen Ltd.
|
6.3% | 2.845 | 2.14% | 4.24x |
|
NSRX
Nasus Pharma
|
-- | 0.000 | -- | -- |
|
PHGE
BiomX, Inc.
|
38.57% | 0.072 | 20.14% | 1.51x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
INCR
InterCure Ltd.
|
-- | -- | -- | -- | -- | -- |
|
CANF
Can-Fite BioPharma Ltd.
|
-- | -- | -- | -- | -- | -- |
|
CGEN
Compugen Ltd.
|
$241K | -$7.9M | -49.12% | -51.8% | -417.4% | -- |
|
NSRX
Nasus Pharma
|
-- | -- | -- | -- | -- | -- |
|
PHGE
BiomX, Inc.
|
-$1.2M | -$8.5M | -116.24% | -160.84% | -- | -$7.2M |
InterCure Ltd. vs. Competitors
-
Which has Higher Returns INCR or CANF?
Can-Fite BioPharma Ltd. has a net margin of -- compared to InterCure Ltd.'s net margin of --. InterCure Ltd.'s return on equity of -- beat Can-Fite BioPharma Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital INCRInterCure Ltd.-- -- $158.1M CANFCan-Fite BioPharma Ltd.-- -- -- -
What do Analysts Say About INCR or CANF?
InterCure Ltd. has a consensus price target of --, signalling upside risk potential of 10.24%. On the other hand Can-Fite BioPharma Ltd. has an analysts' consensus of $3.50 which suggests that it could grow by 1004.1%. Given that Can-Fite BioPharma Ltd. has higher upside potential than InterCure Ltd., analysts believe Can-Fite BioPharma Ltd. is more attractive than InterCure Ltd..
Company Buy Ratings Hold Ratings Sell Ratings INCRInterCure Ltd.0 0 0 CANFCan-Fite BioPharma Ltd.2 0 0 -
Is INCR or CANF More Risky?
InterCure Ltd. has a beta of 0.600, which suggesting that the stock is 40.001% less volatile than S&P 500. In comparison Can-Fite BioPharma Ltd. has a beta of 0.982, suggesting its less volatile than the S&P 500 by 1.756%.
-
Which is a Better Dividend Stock INCR or CANF?
InterCure Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Can-Fite BioPharma Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. InterCure Ltd. pays -- of its earnings as a dividend. Can-Fite BioPharma Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios INCR or CANF?
InterCure Ltd. quarterly revenues are --, which are smaller than Can-Fite BioPharma Ltd. quarterly revenues of --. InterCure Ltd.'s net income of -- is lower than Can-Fite BioPharma Ltd.'s net income of --. Notably, InterCure Ltd.'s price-to-earnings ratio is -- while Can-Fite BioPharma Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for InterCure Ltd. is 0.49x versus 1.77x for Can-Fite BioPharma Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income INCRInterCure Ltd.0.49x -- -- -- CANFCan-Fite BioPharma Ltd.1.77x -- -- --
-
Which has Higher Returns INCR or CGEN?
Compugen Ltd. has a net margin of -- compared to InterCure Ltd.'s net margin of -369.06%. InterCure Ltd.'s return on equity of -- beat Compugen Ltd.'s return on equity of -51.8%.
Company Gross Margin Earnings Per Share Invested Capital INCRInterCure Ltd.-- -- $158.1M CGENCompugen Ltd.12.75% -$0.07 $46.8M -
What do Analysts Say About INCR or CGEN?
InterCure Ltd. has a consensus price target of --, signalling upside risk potential of 10.24%. On the other hand Compugen Ltd. has an analysts' consensus of $6.25 which suggests that it could grow by 278.79%. Given that Compugen Ltd. has higher upside potential than InterCure Ltd., analysts believe Compugen Ltd. is more attractive than InterCure Ltd..
Company Buy Ratings Hold Ratings Sell Ratings INCRInterCure Ltd.0 0 0 CGENCompugen Ltd.4 0 0 -
Is INCR or CGEN More Risky?
InterCure Ltd. has a beta of 0.600, which suggesting that the stock is 40.001% less volatile than S&P 500. In comparison Compugen Ltd. has a beta of 2.818, suggesting its more volatile than the S&P 500 by 181.823%.
-
Which is a Better Dividend Stock INCR or CGEN?
InterCure Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Compugen Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. InterCure Ltd. pays -- of its earnings as a dividend. Compugen Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios INCR or CGEN?
InterCure Ltd. quarterly revenues are --, which are smaller than Compugen Ltd. quarterly revenues of $1.9M. InterCure Ltd.'s net income of -- is lower than Compugen Ltd.'s net income of -$7M. Notably, InterCure Ltd.'s price-to-earnings ratio is -- while Compugen Ltd.'s PE ratio is 55.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for InterCure Ltd. is 0.49x versus 22.05x for Compugen Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income INCRInterCure Ltd.0.49x -- -- -- CGENCompugen Ltd.22.05x 55.83x $1.9M -$7M
-
Which has Higher Returns INCR or NSRX?
Nasus Pharma has a net margin of -- compared to InterCure Ltd.'s net margin of --. InterCure Ltd.'s return on equity of -- beat Nasus Pharma's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital INCRInterCure Ltd.-- -- $158.1M NSRXNasus Pharma-- -- -- -
What do Analysts Say About INCR or NSRX?
InterCure Ltd. has a consensus price target of --, signalling upside risk potential of 10.24%. On the other hand Nasus Pharma has an analysts' consensus of -- which suggests that it could fall by --. Given that InterCure Ltd. has higher upside potential than Nasus Pharma, analysts believe InterCure Ltd. is more attractive than Nasus Pharma.
Company Buy Ratings Hold Ratings Sell Ratings INCRInterCure Ltd.0 0 0 NSRXNasus Pharma0 0 0 -
Is INCR or NSRX More Risky?
InterCure Ltd. has a beta of 0.600, which suggesting that the stock is 40.001% less volatile than S&P 500. In comparison Nasus Pharma has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock INCR or NSRX?
InterCure Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nasus Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. InterCure Ltd. pays -- of its earnings as a dividend. Nasus Pharma pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios INCR or NSRX?
InterCure Ltd. quarterly revenues are --, which are smaller than Nasus Pharma quarterly revenues of --. InterCure Ltd.'s net income of -- is lower than Nasus Pharma's net income of --. Notably, InterCure Ltd.'s price-to-earnings ratio is -- while Nasus Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for InterCure Ltd. is 0.49x versus -- for Nasus Pharma. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income INCRInterCure Ltd.0.49x -- -- -- NSRXNasus Pharma-- -- -- --
-
Which has Higher Returns INCR or PHGE?
BiomX, Inc. has a net margin of -- compared to InterCure Ltd.'s net margin of --. InterCure Ltd.'s return on equity of -- beat BiomX, Inc.'s return on equity of -160.84%.
Company Gross Margin Earnings Per Share Invested Capital INCRInterCure Ltd.-- -- $158.1M PHGEBiomX, Inc.-- -$5.55 $17.1M -
What do Analysts Say About INCR or PHGE?
InterCure Ltd. has a consensus price target of --, signalling upside risk potential of 10.24%. On the other hand BiomX, Inc. has an analysts' consensus of $399.00 which suggests that it could grow by 16252.46%. Given that BiomX, Inc. has higher upside potential than InterCure Ltd., analysts believe BiomX, Inc. is more attractive than InterCure Ltd..
Company Buy Ratings Hold Ratings Sell Ratings INCRInterCure Ltd.0 0 0 PHGEBiomX, Inc.1 0 0 -
Is INCR or PHGE More Risky?
InterCure Ltd. has a beta of 0.600, which suggesting that the stock is 40.001% less volatile than S&P 500. In comparison BiomX, Inc. has a beta of 1.558, suggesting its more volatile than the S&P 500 by 55.818%.
-
Which is a Better Dividend Stock INCR or PHGE?
InterCure Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BiomX, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. InterCure Ltd. pays -- of its earnings as a dividend. BiomX, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios INCR or PHGE?
InterCure Ltd. quarterly revenues are --, which are smaller than BiomX, Inc. quarterly revenues of --. InterCure Ltd.'s net income of -- is lower than BiomX, Inc.'s net income of -$9.2M. Notably, InterCure Ltd.'s price-to-earnings ratio is -- while BiomX, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for InterCure Ltd. is 0.49x versus -- for BiomX, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income INCRInterCure Ltd.0.49x -- -- -- PHGEBiomX, Inc.-- -- -- -$9.2M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Netflix Buy Warner Bros?
Following a bidding war, Netflix (NASDAQ:NFLX) has announced its intention…
Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Stock Ideas
Buy
64
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 40x
Alerts
Sell
50
PLAB alert for Dec 10
Photronics, Inc. [PLAB] is up 45.35% over the past day.
Buy
60
OLMA alert for Dec 10
Olema Pharmaceuticals, Inc. [OLMA] is up 15.35% over the past day.
Buy
84
TSAT alert for Dec 10
Telesat Corp. [TSAT] is up 3.07% over the past day.
